Reaffirmed: BioTime (AMEX:BTX) Buy Rating Reconfirmed by H.C. Wainwright; $4 Target in Place

BioTime, Inc. (NYSEAMERICAN:BTX) Logo

Investors sentiment decreased to 1.19 in Q4 2018. Its down 0.20, from 1.39 in 2018Q3. It is negative, as 10 investors sold BioTime, Inc. shares while 21 reduced holdings. 15 funds opened positions while 22 raised stakes. 52.79 million shares or 4.25% less from 55.13 million shares in 2018Q3 were reported.

Portfolio Solutions Lc reported 1,300 shares. Williams Jones Assoc Ltd Liability Corporation owns 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 80,740 shares. Wells Fargo & Mn owns 59,788 shares. California Employees Retirement stated it has 48,400 shares. Rhumbline Advisers reported 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). 22,784 are held by State Board Of Administration Of Florida Retirement. Moreover, Riggs Asset Managment has 0.01% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 11,600 shares. Tci Wealth Advsr holds 1,300 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 5,234 shares. Citadel Advsrs Limited Liability owns 156,947 shares for 0% of their portfolio. Jefferies Grp Ltd Liability stated it has 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Cwm Limited Liability Corporation invested in 15,200 shares. 25,000 were accumulated by Pembroke Mgmt Ltd. Tower Research Capital Ltd Liability Corporation (Trc) holds 0% or 22,789 shares in its portfolio. Paradigm Fin Ltd Liability reported 10,000 shares stake.

BioTime (AMEX:BTX) Rating Reaffirmed

Recently, In a research report published on Friday morning, BioTime (AMEX:BTX) shares have had their Buy Rating maintained by professional analysts at H.C. Wainwright, who currently has a $4 TP on company. This target by H.C. Wainwright indicates the possibile upside of 131.21 % from the stock close price.

BioTime, Inc. (NYSEAMERICAN:BTX) Ratings Coverage

Among 2 analysts covering BioTime (AMEX:BTX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTime has $4 highest and $3 lowest target. $3.50’s average target is 102.31% above currents $1.73 stock price. BioTime had 6 analyst reports since December 11, 2018 according to SRatingsIntel. As per Thursday, February 21, the company rating was initiated by H.C. Wainwright.

The stock increased 11.61% or $0.18 during the last trading session, reaching $1.73. About 2.53 million shares traded or 143.64% up from the average. BioTime, Inc. (AMEX:BTX) has declined 42.59% since March 16, 2018 and is downtrending. It has underperformed by 46.96% the S&P500.

Analysts await BioTime, Inc. (NYSEAMERICAN:BTX) to report earnings on March, 21. They expect $-0.07 EPS, up 12.50 % or $0.01 from last year’s $-0.08 per share. After $-0.07 actual EPS reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $265.69 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More notable recent BioTime, Inc. (NYSEAMERICAN:BTX) news were published by: Businesswire.com which released: “BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update – Business Wire” on November 08, 2018, also Businesswire.com with their article: “AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance – Business Wire” published on August 16, 2018, Businesswire.com published: “BioTime Warrants to Expire on October 1, 2018 – Business Wire” on September 21, 2018. More interesting news about BioTime, Inc. (NYSEAMERICAN:BTX) were released by: Businesswire.com and their article: “BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company – Business Wire” published on March 11, 2019 as well as Streetinsider.com‘s news article titled: “BioTime (BTX) Names Brian Culley as CEO – StreetInsider.com” with publication date: September 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.